We have previously shown that SHR, like humans with essential hypertension, are insulin resistant. Captopril has been reported to improve both blood pressure and insulin action in hypertensive humans. To determine whether SHR would demonstrate this clinically-significant drug effect, 11-week old male SHR (n=7 per group) were randomly assigned to receive either captopril (50 mg/kg-day in drinking water (C)) or water (W). Animals were treated for four weeks. Data are shown as mean±SD. Weight gain was the same in the two groups while tail systolic blood pressure measured non-invasively was significantly lower (P<0.05 by 2-way ANOVA) in C-treated rats (C = 134±8; W = 177±8 mm Hg, following four weeks of treatment). Insulin action was assessed with oral glucose tolerance tests, after four weeks of treatment. Neither glucose nor insulin values were significantly different between C and W animals (by two-way ANOVA): GLUCOSE (mg/dL) INSULIN (ng/mL) TIME (min) 0 30 60 0 30 60 W 161±61 215±32 236±15 1.79±1.6 1.45±1.12 1.23±.71 C 148±34 231±49 235±53 2.28±1.8 1.6±1.6 1.34±0.84 We conclude that in SHR treated with C for 4 weeks, there was a significant reduction of blood pressure despite no effect en insulin action. This suggests that SHR may be an imperfect model of human essential hypertension.
|Original language||English (US)|
|Journal||Journal of Investigative Medicine|
|State||Published - 1996|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)